Compare Adobe Systems Inc (ADBE) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs BridgeBio Pharma Inc — how do they compare? Adobe Systems Inc trades at $220.64 (market cap $88.06B), while BridgeBio Pharma Inc trades at $78.11 (market cap $15.26B). The key difference: Adobe Systems Inc is far larger — about 5.8× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | BBIO | |
|---|---|---|
Market Cap | $88.06B | $15.26B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $79.91 |
52-Week Low | $193.41 | $43.19 |
Enterprise Value | $89.50B | $16.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $220.94, up 1.32% with strong fundamentals including 29.99% net margin and consistent earnings beats. Technical indicators show bullish momentum with support at $218 and resistance at $228. Recent news highlights institutional buying despite AI competition concerns, while cash flow remains robust at $10.03B from operations in 2025.
Outlook remains positive with a $246.75 analyst target, though risks include AI disruption and CEO transition. Valuation appears attractive with P/E of 12.67, supporting a buy case for long-term growth investors amid near-term volatility.
BridgeBio Pharma (BBIO) trades at $77.91, up 0.93% on the day, supported by a bullish technical outlook and strong analyst consensus. The stock shows robust revenue growth, with 2025 revenue reaching $502.08M, though it remains unprofitable with a net income margin of -124.41%. Recent positive news includes a $1 billion preferred equity raise and regulatory progress for key drug candidates, fueling investor optimism despite ongoing cash burn from operations.
The investment case hinges on the company's pipeline catalysts and commercial execution, with a consensus price target of $102.75 implying significant upside. However, high cash burn, negative equity, and consistent earnings misses present substantial risks, requiring careful monitoring of upcoming clinical and regulatory milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
